buprenorphine


Also found in: Dictionary, Thesaurus, Wikipedia.

buprenorphine

 [bu″prĕ-nor´fēn]
a synthetic opioid agonist-antagonist derived from thebaine, used in the form of the hydrochloride salt as an analgesic for moderate to severe pain and as an anesthesia adjunct. Administered sublingually or by intramuscular or intravenous injection.

buprenorphine

/bu·pre·nor·phine/ (bu″prĕ-nor´fēn) a synthetic opioid agonist-antagonist derived from thebaine, used as the hydrochloride salt as an analgesic and as an anesthesia adjunct.

buprenorphine

(byo͞o′prə-nôr′fēn′)
n.
A semisynthetic opioid drug, C29H41NO4, used usually in its hydrochloride form as an analgesic and, in combination with naloxone, for long-term treatment of addiction to opioids such as heroin.

buprenorphine

[bu′prĕ-nor′fēn]
a synthetic opioid agonist-antagonist derived from thebaine, used in the form of the hydrochloride salt as an analgesic for moderate to severe pain and as an anesthesia adjunct. Administered sublingually or by intramuscular or IV injection.
indications It is administered parenterally for the relief of moderate to severe pain and is used in tablet form to treat opioid dependence.
contraindication This Schedule V controlled substance is contraindicated for patients who may be opioid dependent.
adverse effects Among the reported adverse effects are respiratory depression, sedation, nausea, dizziness, vertigo, headache, vomiting, miosis, diaphoresis, and hypotension.

buprenorphine

A formulation of semi-synthetic opioid which may be superior to methadone in reducing heroin and cocaine abuse/dependence.

Adverse effects
Sedation, constipation.

buprenorphine

Addiction medicine An agent that may be superior to methadone in ↓ heroin and cocaine abuse Side effects Sedation, constipation. Cf Methadone.

buprenorphine

A powerful painkilling drug that binds to the body's opioid receptors. It acts for 6–8 hours. Brand names are Subutex, Temgesic and Transtec.

buprenorphine

an analgesic and opiate antagonist. Its analgesic effects are much greater and last much longer than those of morphine.
References in periodicals archive ?
The flexibility of multi-dose, weekly and monthly injections also enables personalized medication during all stages of the buprenorphine treatment continuum.
The evidence from the trial--the most rigorous to date comparing the two options--all favors buprenorphine, she said.
This study demonstrated that study participants on a full agonist were successfully switched to buprenorphine HCl buccal film, an opioid partial agonist, at approximately 50 percent of the full agonist dose, without the need for an opioid taper and without increasing the risk of withdrawal or loss of pain control," said Lynn Webster, M.
Study OX219-007 (n=310) was a prospective, randomized, multicenter, blinded, parallel-group, active-controlled study comparing advanced formulation ZUBSOLV compared to generic buprenorphine monotherapy for induction of opioid maintenance therapy.
Concerns about cost and diversion have prompted many states to place limits on buprenorphine prescription.
Results--Maximum plasma buprenorphine concentration was achieved within 5 minutes after IM administration.
For example, an area with high rates of uninsured individuals was unlikely to have many credentialed physicians able to prescribe buprenorphine.
8 mg, respectively) or generic buprenorphine monotherapy (8 mg and 8 or 16 mg, respectively).
Providing opioid-dependent patients with high quality generic buprenorphine HCl and naloxone HCl through treatment in physicians' offices, treatment centers, or prescriptions filled at retail pharmacies offers tremendous cost savings for both consumers and the U.
The addition of buprenorphine to their recovery program had provided them with the first real success they had ever experienced.
Also, tramadol is easier to administer in an outpatient setting because it's an oral, nonscheduled medication compared with the sublingual, schedule III buprenorphine.
Initially, the SF OBOT Pilot was intended to provide only methadone, but when buprenorphine became available for office-based use in 2002, the SFDPH saw the opportunity to introduce providers (particularly primary care physicians) to this new treatment option and to develop a city-wide program that would adequately support providers in this new endeavor.